argenx (ARGX) vs Vaxcyte (PCVX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Vaxcyte (PCVX) has outperformed argenx (ARGX) over the past year, gaining 59.6% versus a gain of 2.5%. Over five years, ARGX leads with a +178.7% price change compared with +166.3% for PCVX. argenx is the larger company by market cap ($51.48 billion vs $9.67 billion), about 5.3 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ARGX | PCVX |
|---|---|---|
| Share price | $818.63 | $65.02 |
| Market cap | $51.48B | $9.67B |
| 1-day change | -11.83% | -2.90% |
| YTD return | -2.65% | +40.91% |
| 1-year return | +2.46% | +59.59% |
| 5-year return | +178.69% | +166.35% |
| P/E ratio (TTM) | 31.20 | — |
| Forward P/E | 23.58 | — |
| EPS (TTM) | $26.24 | $-7.62 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Net income (latest FY) | $1.29B | $-766.63M |
| 52-week high | $1,072.75 | $90.75 |
| 52-week low | $661.85 | $39.87 |
| Distance from 52-week high | -23.69% | -28.36% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +43.17% | +79.96% |
| Average volume | 283.40K | 1.66M |
| Shares outstanding | 62.89M | 148.81M |
| Employees | 1,863 | 507 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- argenx is about 5.3 times larger than Vaxcyte by market value ($51.48B vs $9.67B).
- PCVX has outperformed ARGX by 57.1 percentage points over the past year.
About argenx
ARGX stock →argenx SE, a commercial-stage biopharma company, develops various therapies for the treatment of autoimmune diseases in the United States, Japan, China, the Netherlands, and internationally. The company offers VYVGART for the treatment of gMG and immune thrombocytopenia (ITP), and VYVGART HYTRULO for the treatment of gMG and chronic inflammatory demyelinating polyneuropathy (CIDP).
Healthcare · Biotechnology · 1,863 employees
About Vaxcyte
PCVX stock →Vaxcyte, Inc., a clinical-stage vaccine innovation company, develops conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent carrier-sparing investigational pneumococcal conjugate vaccine (PCV) for the prevention of invasive pneumococcal disease (IPD) in infants.
Healthcare · Biotechnology · 507 employees
ARGX vs PCVX FAQ
Which is bigger, argenx or Vaxcyte?
argenx (ARGX) is larger, with a market capitalization of $51.48B compared with $9.67B for Vaxcyte (PCVX).
Which stock has performed better over the past year, ARGX or PCVX?
PCVX returned +59.59% over the past 12 months, compared with +2.46% for ARGX (price return, excluding dividends). Past performance does not predict future results.
Are argenx and Vaxcyte in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.